

# Deepika Dhawan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5008428/publications.pdf>

Version: 2024-02-01

19  
papers

898  
citations

623734

14  
h-index

794594

19  
g-index

19  
all docs

19  
docs citations

19  
times ranked

932  
citing authors

#	ARTICLE	IF	CITATIONS
1	Urinary Bladder Cancer in Dogs, a Naturally Occurring Model for Cancer Biology and Drug Development. <i>ILAR Journal</i> , 2014, 55, 100-118.	1.8	202
2	Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer—Evidence for a Relevant Model System and Urine-Based Diagnostic Test. <i>Molecular Cancer Research</i> , 2015, 13, 993-1002.	3.4	117
3	Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer. <i>PLoS ONE</i> , 2015, 10, e0136688.	2.5	56
4	Targeting Folate Receptors to Treat Invasive Urinary Bladder Cancer. <i>Cancer Research</i> , 2013, 73, 875-884.	0.9	52
5	Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans. <i>Frontiers in Oncology</i> , 2019, 9, 1493.	2.8	51
6	Effects of Short-term Celecoxib Treatment in Patients with Invasive Transitional Cell Carcinoma of the Urinary Bladder. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1371-1377.	4.1	50
7	Canine invasive transitional cell carcinoma cell lines: In vitro tools to complement a relevant animal model of invasive urinary bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 284-292.	1.6	47
8	Multicomponent, peptide-targeted glycol chitosan nanoparticles containing ferrimagnetic iron oxide nanocubes for bladder cancer multimodal imaging. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 4141-4155.	6.7	46
9	Subcutaneous 5-Azacidine Treatment of Naturally Occurring Canine Urothelial Carcinoma: A Novel Epigenetic Approach to Human Urothelial Carcinoma Drug Development. <i>Journal of Urology</i> , 2012, 187, 302-309.	0.4	42
10	Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs. <i>International Journal of Genomics</i> , 2017, 2017, 1-9.	1.6	40
11	Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 897-904.	4.1	39
12	DNMT1: An emerging target in the treatment of invasive urinary bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1761-1769.	1.6	34
13	Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer. <i>PLoS Genetics</i> , 2018, 14, e1007571.	3.5	33
14	Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies. <i>Bladder Cancer</i> , 2018, 4, 149-159.	0.4	27
15	RNAseq expression patterns of canine invasive urothelial carcinoma reveal two distinct tumor clusters and shared regions of dysregulation with human bladder tumors. <i>BMC Cancer</i> , 2020, 20, 251.	2.6	16
16	Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i> -mutated Urothelial Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2177-2188.	4.1	13
17	“Lassie, Toto, and Fellow Pet Dogs: Poised to Lead the Way for Advances in Cancer Prevention. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e667-e672.	3.8	12
18	Phase I/II clinical trial of the targeted chemotherapeutic drug, folate-tubulysin, in dogs with naturally-occurring invasive urothelial carcinoma. <i>Oncotarget</i> , 2018, 9, 37042-37053.	1.8	12

#	ARTICLE	IF	CITATIONS
19	Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model. <i>Bladder Cancer</i> , 2019, 5, 63-71.	0.4	9